PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15751999

A variable-temperature diffuse reflectance infrared fourier transform spectroscopy study of the binding of water and pyridine to the surface of acid-activated metakaolin.

Carolina Belver·Christopher Breen·Francis Clegg·Cesar E Fernandes·Miguel A Vicente
View original source ↗Export metadata ↓

Abstract

Four metakaolins were prepared by heating a Spanish kaolin at 600, 700, 800, and 900 degrees C for 10 h. Following preliminary optimization, these metakaolins were acid activated in 6 M hydrochloric acid at 90 degrees C for 6 h; the samples calcined at 600, 700, and 800 degrees C produced the highest surface area solids and were selected for further study. Variable-temperature diffuse reflectance infrared Fourier transform spectroscopy analysis of the resulting acid-activated metakaolins (AAMKs) identified a wide range of hydrogen bond strengths in adsorbed water at room temperature. Above 300 degrees C it was possible to fit the broad hydroxyl stretching band to seven contributing components at 3730, 3700, 3655, 3615, 3583, 3424, and 3325 cm(-1). As the sample temperature was increased, the 3730 cm(-1) band increased in intensity as the water hydrogen bonded to AlOHAl was thermally desorbed. The other six bands decreased in intensity. The spectra of adsorbed pyridine indicated the presence of both Brönsted and Lewis acid sites on the surface of the air-dried AAMKs. Preheating the AAMK at 200 degrees C prior to pyridine sorption reduced the number of Brönsted acid sites and increased the number of thermally stable Lewis acid sites. A reduction in the amount of adsorbed pyridine after pretreating the AAMK at 400 degrees C was tentatively attributed to a reduction in surface area. This was reflected in fewer thermally stable Lewis acid sites in the AAMK pretreated at 400 degrees C compared to the number present in the sample pretreated at 200 degrees C.

Explore related subjects

Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Carolina Belver, Christopher Breen, Francis Clegg, Cesar E Fernandes, Miguel A Vicente. 2005-03-15. A variable-temperature diffuse reflectance infrared fourier transform spectroscopy study of the binding of water and pyridine to the surface of acid-activated metakaolin.. https://doi.org/10.1021/la048323m

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗